Fuente: New York Post
One and done? Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion. Not only was the experimental treatment successful, but the results were still apparent in some participants 18 months after they received the dose. VERVE-102 may be a revolutionary treatment for bad cholesterol before it leads to heart disease.
Leer en la Fuente
Noticias Relacionadas